Last reviewed · How we verify
Rucacuzumab plus standard therapy
Rucacuzumab is a monoclonal antibody that binds to complement component C1q to inhibit the classical complement pathway, reducing inflammatory and immune-mediated tissue damage.
Rucacuzumab is a monoclonal antibody that binds to complement component C1q to inhibit the classical complement pathway, reducing inflammatory and immune-mediated tissue damage. Used for Lupus nephritis (in combination with standard therapy).
At a glance
| Generic name | Rucacuzumab plus standard therapy |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Monoclonal antibody; complement inhibitor |
| Target | C1q (complement component 1q) |
| Modality | Small molecule |
| Therapeutic area | Immunology; Rheumatology |
| Phase | FDA-approved |
Mechanism of action
By blocking C1q, rucacuzumab prevents activation of the classical complement cascade, which is implicated in various autoimmune and inflammatory conditions. When combined with standard therapy, it aims to reduce complement-driven pathology while allowing standard treatments to work synergistically. This approach is particularly relevant in conditions where complement activation contributes to disease progression.
Approved indications
- Lupus nephritis (in combination with standard therapy)
Common side effects
- Infection
- Infusion-related reactions
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: